TW202233657A - 介白素-18變體及使用方法 - Google Patents

介白素-18變體及使用方法 Download PDF

Info

Publication number
TW202233657A
TW202233657A TW110140842A TW110140842A TW202233657A TW 202233657 A TW202233657 A TW 202233657A TW 110140842 A TW110140842 A TW 110140842A TW 110140842 A TW110140842 A TW 110140842A TW 202233657 A TW202233657 A TW 202233657A
Authority
TW
Taiwan
Prior art keywords
polypeptide
seq
variant
modified
stabilized
Prior art date
Application number
TW110140842A
Other languages
English (en)
Chinese (zh)
Inventor
艾倫 林恩
湯姆 布恩
Original Assignee
美商辛卡Il 18公司
耶魯大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商辛卡Il 18公司, 耶魯大學 filed Critical 美商辛卡Il 18公司
Publication of TW202233657A publication Critical patent/TW202233657A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110140842A 2020-11-02 2021-11-02 介白素-18變體及使用方法 TW202233657A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063108794P 2020-11-02 2020-11-02
US63/108,794 2020-11-02

Publications (1)

Publication Number Publication Date
TW202233657A true TW202233657A (zh) 2022-09-01

Family

ID=81384408

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110140842A TW202233657A (zh) 2020-11-02 2021-11-02 介白素-18變體及使用方法

Country Status (14)

Country Link
US (3) US11850276B2 (cg-RX-API-DMAC7.html)
EP (1) EP4236990A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023550545A (cg-RX-API-DMAC7.html)
KR (1) KR20230117120A (cg-RX-API-DMAC7.html)
CN (1) CN116723851A (cg-RX-API-DMAC7.html)
AR (1) AR123978A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021371040C1 (cg-RX-API-DMAC7.html)
CA (1) CA3197145A1 (cg-RX-API-DMAC7.html)
GB (1) GB2617483B (cg-RX-API-DMAC7.html)
IL (1) IL302517A (cg-RX-API-DMAC7.html)
MX (1) MX2023005068A (cg-RX-API-DMAC7.html)
NZ (1) NZ800435A (cg-RX-API-DMAC7.html)
TW (1) TW202233657A (cg-RX-API-DMAC7.html)
WO (1) WO2022094473A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7795181B2 (ja) 2017-09-06 2026-01-07 イェール ユニバーシティー インターロイキン-18バリアントとその利用法
WO2023010021A1 (en) 2021-07-27 2023-02-02 Xencor, Inc. Il-18-fc fusion proteins
EP4469065A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
WO2024044780A1 (en) * 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
EP4584287A1 (en) * 2022-09-06 2025-07-16 TJ Biopharma (Shanghai) Co., Ltd. Il-18 variant polypeptides
WO2024102693A2 (en) 2022-11-07 2024-05-16 Xencor, Inc. Il-18-fc fusion proteins
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
EP4655310A2 (en) * 2023-01-24 2025-12-03 Simcha Il-18, Inc. Methods and compositions for combination therapy
WO2024259270A2 (en) * 2023-06-16 2024-12-19 Simcha IL-18, Inc. Administration of engineered interleukin-18 therapeutics
IL325907A (en) 2023-07-13 2026-03-01 Iovance Biotherapeutics Inc Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
US20250188166A1 (en) 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
WO2025085447A1 (en) 2023-10-17 2025-04-24 Xencor, Inc. Pd-1 targeted il18-fc fusion proteins
WO2025122614A1 (en) 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Il18 receptor agonists and methods of use thereof
CN120189493A (zh) * 2023-12-22 2025-06-24 广州威溶特医药科技有限公司 Dr-18和m1病毒在制备抗肿瘤药物中的应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025151273A1 (en) * 2024-01-08 2025-07-17 Adimab, Llc Il-18 polypeptides and uses thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026006784A1 (en) 2024-06-28 2026-01-02 Iovance Biotherapeutics, Inc. Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
WO2026050249A1 (en) * 2024-08-26 2026-03-05 Simcha IL-18, Inc. Methods of treating cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
EP1669454A3 (en) 1996-06-27 2009-04-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
JP4024366B2 (ja) 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
JP2007143555A (ja) * 1996-11-29 2007-06-14 Hayashibara Biochem Lab Inc ポリペプチド
JP3955352B2 (ja) 1997-02-25 2007-08-08 株式会社林原生物化学研究所 破骨細胞形成阻害剤
TWI227136B (en) 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
AU2001275166B2 (en) 2000-06-02 2005-07-28 Smithkline Beecham Corporation Methods of treating viral diseases with il-18 and il-18 combinations
JP2004530432A (ja) 2001-03-08 2004-10-07 アレス・トレーディング・ソシエテ・アノニム インターロイキン−18変異体、その産生および使用
US6800479B2 (en) 2001-12-11 2004-10-05 Samyang Genex Corporation Recombinant adenoviruses expressing interleukin-18 protein and gene therapy using them
EP1613274B1 (en) * 2003-04-15 2010-03-03 GlaxoSmithKline LLC Human il-18 substitution mutants and their conjugates
WO2005075648A1 (en) * 2004-01-28 2005-08-18 Gifu University Interleukin-18 mutant proteins
WO2011080733A1 (en) * 2010-01-04 2011-07-07 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
WO2017102010A1 (en) 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
JP7795181B2 (ja) * 2017-09-06 2026-01-07 イェール ユニバーシティー インターロイキン-18バリアントとその利用法
JP2020143000A (ja) * 2019-03-04 2020-09-10 大陽日酸株式会社 融合タンパク質及びその製造方法、目的タンパク質の製造方法
US12029778B2 (en) * 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
CN116368148A (zh) * 2020-08-19 2023-06-30 明峰治疗股份公司 修饰的il-18多肽及其用途

Also Published As

Publication number Publication date
US11850276B2 (en) 2023-12-26
AR123978A1 (es) 2023-02-01
MX2023005068A (es) 2023-07-14
GB2617483B (en) 2025-03-12
EP4236990A1 (en) 2023-09-06
GB202308183D0 (en) 2023-07-19
WO2022094473A1 (en) 2022-05-05
JP2023550545A (ja) 2023-12-01
US12582701B2 (en) 2026-03-24
NZ800435A (en) 2025-12-19
US20230277625A1 (en) 2023-09-07
US20240066100A1 (en) 2024-02-29
AU2021371040C1 (en) 2025-05-29
AU2025203386A1 (en) 2025-06-05
US12564621B2 (en) 2026-03-03
KR20230117120A (ko) 2023-08-07
AU2021371040B2 (en) 2025-02-13
US20240075104A1 (en) 2024-03-07
EP4236990A4 (en) 2025-03-19
AU2021371040A1 (en) 2023-06-22
IL302517A (en) 2023-07-01
CA3197145A1 (en) 2022-05-05
GB2617483A (en) 2023-10-11
CN116723851A (zh) 2023-09-08

Similar Documents

Publication Publication Date Title
US12582701B2 (en) Interleukin-18 variants and methods of use
US12403180B2 (en) Interleukin-18 variants and methods of use
US20240374679A1 (en) Interleukin-18 mimics and methods of use
EP4556486A1 (en) Trispecific antibody and use thereof
US20220023420A1 (en) Fusion constructs and methods of using thereof
RU2797536C2 (ru) Варианты интерлейкина-18 и способы их применения
HK40100300A (en) Interleukin-18 variants and methods of use
HK40081595A (zh) 三特异性抗体及其用途